# Netris Pharma

Source: https://onco.cc/companies/netris-pharma/  
OnCo record `netris-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Netris Pharma is a Lyon biotech built on Patrick Mehlen's discovery that tumours use the guidance protein netrin-1 to survive; its antibody NP137 blocks netrin-1 and has shown activity in endometrial cancer.

## Summary

Netris Pharma develops therapies that restore the cell death normally triggered by dependence receptors when their ligand is absent. NP137 is a humanised antibody that neutralises netrin-1, a ligand many tumours over-produce to block this apoptosis. In a phase 1 study it was safe and produced responses in endometrial carcinoma, and a Nature paper in 2023 showed it reverses epithelial-to-mesenchymal transition and sensitises tumours to chemotherapy. It is being tested with carboplatin and paclitaxel, and with pembrolizumab, in endometrial and cervical cancers.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: NETRIS Pharma SAS
- Tags: drug-maker
- HQ: Lyon
- Type: biotech
- Website: https://www.netrispharma.com/

## Sources

- Official website: https://www.netrispharma.com/

## Connected records

- drugs: [NP137](https://onco.cc/drugs/np137/)

---
JSON: https://onco.cc/api/v1/entities/netris-pharma.json